EmergentMedTech Merges with TRU Biologix

BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business

January 22, 2026

Medical Devices

BioStem Technologies (OTC: BSEM) has acquired the surgical and wound care business of BioTissue Holdings, Inc. for approximately $15 million upfront, with up to $25 million of contingent milestone and royalty payments. The deal includes the Neox and Clarix product lines, a nationwide commercial sales organization and assigned GPO contracts, expanding BioStem's access into hospital inpatient and outpatient wound-care markets and adding assets that generated roughly $29 million in 2025.

Emergence Acquires MedEvolve

November 11, 2025

Healthcare Services

Emergence, an enterprise backed by The Pritzker Organization, has acquired MedEvolve, an AI-powered revenue cycle automation and analytics provider. The acquisition combines MedEvolve’s Effective Intelligence platform with Emergence’s software expertise and long-term capital to accelerate AI-driven capabilities for healthcare revenue cycle management.

Medix Biochemica Group Acquires Bioresource Technology (BRT)

June 21, 2022

Biotechnology

Medix Biochemica has acquired a 100% stake in US-based Bioresource Technology (BRT) to expand its base matrix capabilities and strengthen its presence in the United States. BRT will be integrated into Medix Biochemica’s IVD Biomaterials Business Unit (St. Louis) while operations continue in Weston, Florida, and BRT leadership will serve as strategic advisors.

ORHub, Inc. Acquires PUR Biologics, LLC

April 25, 2022

Medical Devices

ORHub, Inc. (OTC: ORHB) purchased 100% of the equity interest and assets of PUR Biologics, LLC, acquiring proprietary regenerative therapeutic and bone regeneration product technologies. The acquisition enables ORHub to enter the global medical device market and expand its regenerative therapeutic capabilities as it updates corporate branding and prepares for an audit and potential up-listing.

Convatec Group Acquires Triad Life Sciences

January 28, 2022

Medical Devices

Convatec Group Plc has signed a definitive agreement to acquire Triad Life Sciences Inc, a Memphis-based developer and manufacturer of porcine placenta‑derived extracellular matrix products for advanced wound care. The deal, expected to close in Q1 2022 subject to regulatory approvals, values Triad at an initial $125 million with up to $275 million additional contingent/earnout payments tied to milestones and performance.

ERT Merges with Bioclinica to Create Global Clinical Trial Endpoint Leader

December 10, 2020

Healthcare Services

ERT has merged with Bioclinica to create a global leader in clinical trial endpoint technology, combining Bioclinica's imaging and eClinical capabilities with ERT's expertise in eCOA, cardiac safety, respiratory and wearables. The transaction was completed in 2021 with Cinven (Bioclinica's owner) becoming a significant minority shareholder in ERT alongside Nordic Capital, Astorg and Novo Holdings A/S.